Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14629947 | 0.80 | KMT2A (0.44) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4412110 | 0.79 | MAPT (0.53) | MAPTLMNAALDH1A1POLBHTT | |
| SCHEMBL14629929 | 0.78 | CNR2 (0.39) | MAPTLMNAPOLBTP53MEN1 | |
| SCHEMBL17936805 | 0.67 | TSHR (0.45) | MAPTLMNAALDH1A1POLBHTT | |
| SCHEMBL14094214 | 0.66 | ALDH1A1 (0.42) | ALDH1A1HTTALOX15ATM | |
| SCHEMBL840359 | 0.65 | — | — | |
| SCHEMBL28309397 | 0.65 | — | — | |
| SCHEMBL15611429 | 0.65 | — | — | |
| SCHEMBL4198070 | 0.65 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15612083 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734507-B1 | PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED CYCLIC ALKYLENE UREAS | ALLNEX IP S À R L (LU) | 2017-05-31 | — | — | EP | disclosed |
| US-9440928-B2 | Process for the synthesis of N-substituted cyclic alkylene ureas | Allnex IP S.ar.L. (LU) | 2016-09-13 | — | — | US | disclosed |
| US-20140179931-A1 | Process for the Synthesis of N-Substituted Cyclic Alkylene Ureas | ALLNEX USA INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2734507-A1 | PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED CYCLIC ALKYLENE UREAS | Allnex IP S.à.r.l. (LU) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013012995-A1 | PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED CYCLIC ALKYLENE UREAS | CYTEC TECHNOLOGY CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2548869-A1 | Process for the Synthesis of N-substituted Cyclic Alkylene Ureas | Cytec Technology Corp. (US) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179931-A1 | Process for the Synthesis of N-Substituted Cyclic Alkylene Ureas | CA4, CA2, CDYL | MAPT 3778/4885LMNA 1882/4885NPSR1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.